Camilla Macapili Languille is the Head of Life Sciences within Mubadala’s Direct Investments platform where she is responsible for the fund’s international healthcare investments across the pharmaceuticals, medtech, tools & diagnostics, healthcare IT, provision, biotech, and animal health sectors, spanning multiple asset classes (private equity, public equities, funds). Camilla joined Mubadala in 2013 and has c. 20 years of experience working across multiple industries within the corporate finance and principal investment fields in North America, Europe and MENA, with a focus on healthcare and technology. Prior to Mubadala, Camilla worked in M&A and investments for Daiwa Capital and Société Générale based in Paris, and in investments for Virgin Group’s headquarters in London, where she managed the Special Situations portfolio and helped to launch Virgin Healthcare. She began her career in Healthcare M&A for JPMorgan in New York and London, focusing on pharma, medtech and biotech. She currently serves on the Boards of PCI Pharma, Envision Pharma Group, and Rodenstock. Camilla holds a Bachelor’s degree (summa cum laude) in Economics & Political Science from Columbia University of New York. She is a Canadian national and is fluent in English and French.